Ocular Therapeutix SG&A Expenses 2013-2024 | OCUL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Ocular Therapeutix sg&a expenses from 2013 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Ocular Therapeutix sg&a expenses from 2013 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$88.1B
Takeda Pharmaceutical (TAK)	$44.8B
Merck (MKGAF)	$21.8B
Astellas Pharma (ALPMY)	$20.6B
Sandoz Group AG (SDZNY)	$18.4B
Summit Therapeutics (SMMT)	$17B
United Therapeutics (UTHR)	$16.5B
Shionogi (SGIOY)	$12.2B
Neurocrine Biosciences (NBIX)	$12B
Catalent (CTLT)	$10.9B
Orion OYJ (ORINY)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$7.1B
Ionis Pharmaceuticals (IONS)	$5.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.5B
Corcept Therapeutics (CORT)	$4.9B
Crinetics Pharmaceuticals (CRNX)	$4.7B
Madrigal Pharmaceuticals (MDGL)	$4.7B
Dyne Therapeutics (DYN)	$3.6B
PTC Therapeutics (PTCT)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Soleno Therapeutics (SLNO)	$2.1B
Recursion Pharmaceuticals (RXRX)	$2B
Harrow (HROW)	$1.9B
Centessa Pharmaceuticals (CNTA)	$1.8B
NewAmsterdam Pharma (NAMS)	$1.7B
ARS Pharmaceuticals (SPRY)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Xencor (XNCR)	$1.5B